STOCK TITAN

ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

CRISPR Therapeutics reported a Schedule 13G/A showing 11,313,623 shares beneficially owned (representing 11.79% of the common stock). The filing attributes ownership to ARK Investment Management LLC and Catherine D. Wood, with ARK holding 10,545,920 shares of sole voting power and total dispositive power over 11,313,623 shares. The amendment is signed and dated 04/30/2026. The filing notes ARK Innovation ETF as a client holding more than 5% within ARK's client list.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake disclosed: ARK and Wood hold 11.79% of CRISPR Therapeutics.

ARK Investment Management LLC and Catherine D. Wood are reported as beneficial owners of 11,313,623 shares, a stake above the 5% threshold that triggers Schedule 13G/A reporting. The breakdown shows ARK holds sole voting power for 10,545,920 shares and sole dispositive power over 11,313,623 shares.

Subsequent trading activity by ARK or the ARK Innovation ETF could affect public float; future public filings may show if this position changes.

The amendment updates beneficial ownership reporting and identifies client-level interest.

The Schedule 13G/A lists ARK and Catherine D. Wood with combined beneficial ownership of 11,313,623 shares (11.79%). The filing includes a disclosure that ARK Innovation ETF is a client holding over 5% within ARK’s client list.

Signatures are dated 04/30/2026; this satisfies the reporting requirement for substantial passive investors under SEC rules reflected in the amendment.

Beneficial ownership 11,313,623 shares Combined ARK and Catherine D. Wood position
Percent of class 11.79% Percentage of common stock beneficially owned
ARK sole voting power 10,545,920 shares Sole power to vote or to direct the vote
Shared voting power (Wood) 10,754,100 shares Catherine D. Wood shared power to vote
ARK sole dispositive power 11,313,623 shares Sole power to dispose or to direct the disposition
Signature date 04/30/2026 Filing signatures dated
Schedule 13G/A regulatory
"Amendment No. 13 ) CRISPR Therapeutics AG Common Stock"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially owned financial
"Amount beneficially owned: ARK and Catherine D. Wood: 11,313,623"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: ARK: 11,313,623"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
investment company financial
"ARK Innovation ETF, a series of a Delaware statutory trust"





H17182108

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ARK Investment Management LLC
Signature:/s/ Kellen Carter
Name/Title:Kellen Carter, Chief Compliance Officer
Date:04/30/2026
Catherine D. Wood
Signature:/s/ Catherine D. Wood
Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:04/30/2026